文献速递乳房整形与再造美容整形

脂肪移植联合扩增脂肪来源基质细胞用于乳房增大:一项随机对照试验

Fat Grafting With Expanded Adipose-Derived Stromal Cells for Breast Augmentation: A Randomized Controlled Trial.
PubMed 文献 · Aesthet Surg J · 2022-01-01

这项双盲随机对照试验纳入10名30至45岁健康女性,每人的一侧乳房接受含扩增脂肪来源基质细胞(10 × 10^6 ASCs/mL脂肪移植物)的脂肪移植,对侧接受等量安慰剂富集脂肪移植。随访1年MRI显示,ASCs富集侧脂肪移植体积保留率为54.0%(95% CI,30.4%-77.6%),安慰剂富集侧为55.9%(95% CI,28.9%-82.9%)(P = 0.566)。结论不支持ASCs富集脂肪移植优于标准脂肪移植。

要点

  • 10名健康女性完成双侧乳房脂肪移植并随访1年,无严重不良事件。
  • ASCs富集侧脂肪移植1年体积保留率54.0%,对侧安慰剂富集侧55.9%,两组差异无统计学显著(P = 0.566)。
  • 作者结论认为本试验结果不支持ASCs富集脂肪移植在乳房增大中优于标准脂肪移植。

核心结论

  • 本试验结果不支持ASCs富集脂肪移植在乳房增大中优于标准脂肪移植。

研究设计与样本

  • 双盲、随机对照试验,纳入10名30至45岁健康女性,每人的一侧乳房接受含ASCs(10 × 10^6 ASCs/mL脂肪移植物)的300至350 mL脂肪移植,对侧接受等量安慰剂富集脂肪移植。

主要发现

  • 随访1年,ASCs富集脂肪移植侧乳房(n = 10)脂肪移植体积保留率为54.0%(95% CI,30.4%-77.6%),对侧安慰剂富集脂肪移植侧乳房(n = 10)为55.9%(95% CI,28.9%-82.9%)(P = 0.566)。
  • 全部10名参与者完成治疗和随访,未发生严重不良事件。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The main challenge with fat grafting is loss of some of the graft to postsurgery resorption. Previous studies suggest that adipose-derived stromal cells (ASCs) can improve the volume retention of fat grafts but there is a lack of randomized trials to support the use of ASCs in clinical practice. OBJECTIVES: This trial aimed to investigate whether ASCs improve fat graft volume retention in patients undergoing breast augmentation with lipofilling. METHODS: This was a double-blind, randomized controlled trial of breast augmentation with ASC-enriched fat grafting. Healthy women aged 30 to 45 years were enrolled. First, the participants underwent liposuction to obtain fat for culture expansion of ASCs. Then, the participants were randomly assigned to undergo a 300- to 350-mL breast augmentation with ASC-enriched fat grafting (10 × 106 ASCs/mL fat graft) to 1 of their breasts and placebo-enriched fat grafting of identical volume to the contralateral breast. The primary outcome was fat graft volume retention after a 1-year follow-up measured with MRI. The trial is registered at www.clinicaltrialsregister.eu (EudraCT-2014-000510-59). RESULTS: Ten participants were included in the trial; all completed the treatment and follow-up. No serious adverse events occurred. Fat graft volume retention after 1 year was 54.0% (95% CI, 30.4%-77.6%) in the breasts treated with ASC-enriched fat grafting (n = 10) and 55.9% (95% CI, 28.9%-82.9%) in the contralateral breasts treated with placebo-enriched fat grafting (n = 10) (P = 0.566). CONCLUSIONS: The findings of this trial do not support that ASC-enriched fat grafting is superior to standard fat grafting for breast augmentation.

来源:Aesthet Surg J,查看原文。版权归原作者所有。

引用

  1. Vester-Glowinski PV, Herly M, Ørholt M, et al. Fat Grafting With Expanded Adipose-Derived Stromal Cells for Breast Augmentation: A Randomized Controlled Trial. Aesthet Surg J. 2022. PMID: 35704475. doi:10.1093/asj/sjac159

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。